Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy

Wenqing Li, Xinfu Zhang, Chengxiang Zhang, Jinyue Yan, Xucheng Hou, Shi Du, Chunxi Zeng, Weiyu Zhao, Binbin Deng, David W. McComb, Yuebao Zhang, Diana D. Kang, Junan Li, William E. Carson, Yizhou DongNature Communications 2021 · DOI

TL;DR

This paper introduces a novel approach to cancer immunotherapy by using biomimetic nanoparticles to deliver mRNA encoding costimulatory receptors directly to T cells within tumors. This strategy, when combined with existing antibody therapies, significantly enhances the immune system's ability to fight cancer, leading to complete tumor eradication and long-term immunity in some cases.

What Problem Does This Paper Address?

Current cancer immunotherapies, particularly those using antibodies to target immune checkpoints like PD-1 and CTLA-4, have shown great promise but often have limited efficacy, with only about 25% of patients experiencing a significant response. A key limitation is that the tumor microenvironment often lacks sufficient expression of crucial costimulatory molecules, which are essential for fully activating T cells to attack cancer. While antibodies can target these molecules, their effectiveness is hampered if the target isn't readily available on the T cells within the tumor. This paper addresses this by proposing a way to increase the expression of these costimulatory receptors directly on tumor-infiltrating T cells, thereby making them more responsive to immunotherapy.

Methods

The researchers designed and synthesized a library of biomimetic nanoparticles based on phospholipids and glycolipids, which are natural components of cell membranes. They found that a specific phospholipid nanoparticle, PL1, was particularly effective at delivering mRNA to T cells, both in lab cultures (in vitro) and within living organisms (in vivo).

Key techniques and approaches include:

  • Nanoparticle Synthesis and Characterization: A library of phospholipid (PL) and glycolipid (GL) derivatives was synthesized. These were then formulated into nanoparticles with mRNA. Characterization involved techniques like NMR, mass spectroscopy, cryo-TEM for morphology, and dynamic light scattering for size and zeta potential.
  • mRNA Delivery and Expression: Nanoparticles were loaded with mRNA encoding costimulatory receptors (CD137 or OX40) or reporter genes (luciferase, GFP). Delivery efficiency was assessed using luminescence assays and flow cytometry to measure protein expression on T cells.
  • In Vivo Studies: The efficacy of the nanoparticle-mRNA-antibody combination therapy was tested in mouse models of melanoma (B16F10), lymphoma (A20), and colon carcinoma (CT26). Tumor growth, survival rates, and immune cell infiltration were analyzed.
  • Immunological Assays: Flow cytometry was used to analyze the expression of costimulatory receptors on T cells and dendritic cells (DCs), as well as the presence of different immune cell populations within tumors. Cytokine and chemokine levels were measured using Luminex assays and ELISA.
  • Rechallenge Experiments: Mice that achieved complete tumor remission were rechallenged with tumor cells to assess the development of long-term immunity.

Datasets

Not discussed in the paper. The study primarily relies on in vitro cell culture experiments and in vivo animal models.

Key Insights and Ideas

  • Biomimetic Nanoparticles as mRNA Carriers: The development of PL1 nanoparticles demonstrates a promising platform for delivering mRNA to specific cell types, particularly T cells, within the complex tumor microenvironment. Their biomimetic nature likely aids in cellular uptake.
  • Directly Boosting Costimulatory Receptor Expression: Instead of relying solely on antibodies to engage existing costimulatory receptors, this approach increases the number of these receptors on T cells. This is crucial because low expression is a major bottleneck for current therapies.
  • Synergy with Existing Immunotherapies: The combination of PL1-OX40 mRNA and anti-OX40 antibody showed significantly better results than the antibody alone. Furthermore, this combination dramatically enhanced the efficacy of established checkpoint inhibitors (anti-PD-1 + anti-CTLA-4), suggesting a broad applicability.
  • Induction of Long-Term Immunity: In the A20 lymphoma model, a significant portion of mice treated with the combined therapy achieved complete remission and were resistant to tumor rechallenge, indicating the development of durable anti-tumor immunity.
  • Dual Action on T cells and Dendritic Cells: The treatment not only boosted OX40 expression on T cells but also on dendritic cells, suggesting a multi-pronged attack that activates both direct tumor killing by T cells and enhanced antigen presentation by DCs.

Key Results

  • Enhanced Tumor Regression: The combination of PL1-OX40 mRNA and anti-OX40 antibody led to significantly improved tumor regression compared to anti-OX40 antibody alone in multiple tumor models.
  • High Complete Response Rate: In the A20 tumor model, the PL1-OX40 mRNA + anti-OX40 antibody treatment achieved a 60% complete response rate.
  • Rechallenge Resistance: Mice that achieved complete remission in the A20 model were resistant to subsequent tumor rechallenge.
  • Synergy with Checkpoint Inhibitors: The PL1-OX40 mRNA + anti-OX40 antibody combination significantly boosted the antitumor response when added to anti-PD-1 + anti-CTLA-4 antibody therapy in the B16F10 model.
  • Increased Immune Cell Infiltration: Treatment led to increased infiltration of CD8+ T cells into tumors and lungs.

Limitations and Future Work

  • Tumor Model Specificity: While effective in several models, the authors note that the varied immunotherapeutic effects across different tumor models may be due to differences in the tumor microenvironment and immune cell composition. Further investigation into these mechanisms is warranted.
  • Optimization of mRNA Modifications: The study explored pseudouridine (ψ)-modified mRNA (OX40 (ψ)) to improve stability and reduce innate immune responses, suggesting ongoing optimization of mRNA delivery.
  • Systemic Delivery: While intratumoral injection was primarily used, the study also explored systemic administration, particularly in the context of lung metastasis, indicating potential for broader application.
  • Further Exploration of Costimulatory Receptors: The paper highlights the potential for exploring other costimulatory receptors beyond CD137 and OX40, suggesting a broad foundation for future combination therapies.
  • Clinical Translation: The ultimate goal is to translate these findings into human therapies, which will require extensive preclinical and clinical trials to assess safety and efficacy in patients.

Summary updated

Abstract

Antibodies targeting costimulatory receptors of T cells have been developed for the activation of T cell immunity in cancer immunotherapy. However, costimulatory molecule expression is often lacking in tumor-infiltrating immune cells, which can impede antibody-mediated immunotherapy. Here, we hypothesize that delivery of costimulatory receptor mRNA to tumor-infiltrating T cells will enhance the antitumor effects of antibodies. We first design a library of biomimetic nanoparticles and find that phospholipid nanoparticles (PL1) effectively deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Then, we demonstrate that the combination of PL1-OX40 mRNA and anti-OX40 antibody exhibits significantly improved antitumor activity compared to anti-OX40 antibody alone in multiple tumor models. This treatment regimen results in a 60% complete response rate in the A20 tumor model, with these mice being resistant to rechallenge by A20 tumor cells. Additionally, the combination of PL1-OX40 mRNA and anti-OX40 antibody significantly boosts the antitumor immune response to anti-PD-1 + anti-CTLA-4 antibodies in the B16F10 tumor model. This study supports the concept of delivering mRNA encoding costimulatory receptors in combination with the corresponding agonistic antibody as a strategy to enhance cancer immunotherapy.
BibTeX
@inproceedings{li2021biomimetic,
  author = {Wenqing Li and Xinfu Zhang and Chengxiang Zhang and Jinyue Yan and Xucheng Hou and Shi Du and Chunxi Zeng and Weiyu Zhao and Binbin Deng and David W. McComb and Yuebao Zhang and Diana D. Kang and Junan Li and William E. Carson and Yizhou Dong},
  title = {{Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy}},
  booktitle = {Nature Communications},
  year = {2021},
  doi = {10.1038/s41467-021-27434-x},
}
Figure